XML 26 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities        
Net loss $ (10,541,576) $ (5,608,568) $ (28,180,084) $ (7,723,404)
Stock-based compensation expense 1,425,133 250,887 902,946 1,017,938
Depreciation, amortization and accretion 1,722,965 242,427 874,789 118,202
Asset impairment     7,500,000 0
Issuance of restricted stocks 156,814 0    
Amortization of debt issuance costs 0 147,805 182,759 0
Amortization of beneficial conversion feature     4,943,073 0
Noncash interest expense     221,024 0
Derivative (income) expense (196,148) 78,038 12,572 0
Amortization of prepaid research and development - related party 60,992 60,991 121,983 121,984
Common stock issued to executives 509,996 0    
Issuance of warrants to initial investors 596,434 0    
Unrealized (gain) on investment (230,936) 0 971,629 0
Deferred taxes     0 (23,910)
Adjustments to reconcile net loss to net cash used in operating activities:        
(Increase) in accounts receivable (419,966) (131,408) (5,369) (157,058)
Decrease (increase) in inventory 85,741 (613,673) (485,265) (39,442)
(Increase) in prepaid expenses and other (221,015) (370,656) 155,330 150,434
(Increase) in prepaid research and development - related party     0 (150,000)
(Decrease) in accounts payable and accrued liabilities (434,231) (126,781) 1,623,469 547,314
Increase in related party payable 0 38,451    
(Decrease) increase in accrued compensation (681,432) 296,081 1,004,427 196,503
Increase in interest payable 0 161,988 0 (607,061)
(Decrease) increase in deferred rent (1,350) 10,245 10,875 0
(Decrease) in deferred revenue 0 (42,857) (511,607) (85,714)
Net cash used in operating activities (8,168,579) (5,607,030) (10,657,449) (6,634,214)
Cash flows used in investing activities        
Deposits 0 1,998 1,998 (4,886)
Purchases of fixed assets (44,876) (125,161) (252,932) 0
Purchase of ProstaScint Business     0 (1,000,000)
Purchase of Primsol asset (750,000) (540,000) (1,040,000)  
Purchase of Natesto license (2,000,000) 0 (2,000,000)  
Investment in Acerus     (2,012,991)  
Net cash used in investing activities (2,794,876) (663,163) (5,303,925) (1,004,886)
Cash flows from financing activities        
Proceeds from convertible note from Ampio converted to stock     0 7,400,000
Ampio stock subscription payment 0 5,000,000 5,000,000 5,000,000
Proceeds from convertible promissory notes, net 0 5,175,000 5,175,000 0
Debt issuance costs (Note 7) 0 (298,322) (298,322) 0
Costs related to the conversion of the convertible promissory notes to equity     (29,754) 0
Luoxis option payout pursuant to the merger     0 (27,476)
Liabilities paid out pursuant to the merger     0 (20,013)
Sale of stock subscription     200,000 0
Issuance of common stock to Lincoln Park Capital 631,481 0 7,520,493 0
Costs related to sale of common stock (24,247) 0 (904,914) 0
Registered offering of common stock and warrants 8,602,500 0    
Registered offering costs (997,865) 0    
Over-allotment warrants purchased by placement agents 2,852      
Net cash provided by financing activities 8,214,721 9,876,678 16,662,503 12,352,511
Net change in cash, cash equivalents and restricted cash (2,748,734) 3,606,485 701,129 4,713,411
Cash, cash equivalents and restricted cash at beginning of period 8,054,190 7,353,061 7,353,061 2,639,650
Cash, cash equivalents and restricted cash at end of period 5,305,456 10,959,546 8,054,190 7,353,061
Non-cash transactions:        
Ampio stock subscription     0 5,000,000
Ampio unpaid debt converted to stock, received prior to 2015     0 4,600,000
Contingent consideration related to the ProstaScint purchase     0 664,000
Warrant derivative liability related to the issuance of the convertible promissory notes 0 102,931 102,931 0
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 0 1,077,000 1,077,000 0
Fixed asset purchases included in accounts payable 61,241 7,708    
Conversion of convertible promissory notes and interest of $221,000 to common stock     5,396,024 0
Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325     5,379,675 0
Warrants issued in connection with the equity financing to the placement agents $ 292,630 $ 0 297,317 0
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes     136,828 0
Beneficial conversion feature related to convertible promissory notes     4,943,073 0
Debt issuance costs related to notes that converted to equity     $ (218,494) $ 0